The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Engineered antibody fragments and the rise of single domains
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,790
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Self-citationChemical remodelling of cell surfaces in living animals
Prescher, J. A., Dube, D. H., & Bertozzi, C. R. (2004) · Nature · doi:10.1038/nature02791 · Cited by 842
Antibody Multispecificity Mediated by Conformational Diversity
James, L. C., Roversi, P., & Tawfik, D. S. (2003) · Science · doi:10.1126/science.1079731 · Cited by 719
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cited by
Electrochemical Biosensors - Sensor Principles and Architectures
Grieshaber, D., MacKenzie, R., Vörös, J., & Reimhult, E. (2008) · Sensors · doi:10.3390/s80314000 · Cited by 2,329
“Such small, recombinant antibody fragments can be linked to other molecules, for example lipids, drugs and proteins [227].”
BackgroundNanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Richardson, D. S., & Lichtman, J. W. (2015) · Cell · doi:10.1016/j.cell.2015.06.067 · Cited by 1,095
Strategies for the intracellular delivery of nanoparticles
Chou, L. Y. T., Ming, K., & Chan, W. C. W. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00003e · Cited by 811
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“As compared to human VH domains, the VHH FRs show a high sequence homology of more than 80%, and their 3D structures can be superimposed (Muyldermans et al. 2001; Holliger and Hudson 2005).”
BackgroundAntibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Heinis, C., Rutherford, T., Freund, S., & Winter, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.184 · Cited by 743
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 668
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Sakamoto, S., Putalun, W., Vimolmangkang, S., Phoolcharoen, W., Shoyama, Y., Tanaka, H., & Morimoto, S. (2018) · Journal of Natural Medicines · doi:10.1007/s11418-017-1144-z · Cited by 602
Superparamagnetic Iron Oxide Nanoparticles—Current and Prospective Medical Applications
Dulińska-Litewka, J., Łazarczyk, A., Hałubiec, P., Szafrański, O., Karnas, K., & Karewicz, A. (2019) · Materials · doi:10.3390/ma12040617 · Cited by 580
Recent advances in large-scale production of monoclonal antibodies and related proteins
Shukla, A. A., & Thömmes, J. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 578
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Microfluidic Chips for Point‐of‐Care Immunodiagnostics
Gervais, L., de Rooij, N., & Delamarche, E. (2011) · Advanced Materials · doi:10.1002/adma.201100464 · Cited by 491
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
Antibody fragments: Hope and hype
Nelson, A. L. (2010) · mAbs · doi:10.4161/mabs.2.1.10786 · Cited by 463
Foudeh, A. M., Fatanat Didar, T., Veres, T., & Tabrizian, M. (2012) · Lab on a Chip · doi:10.1039/c2lc40630f · Cited by 457
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
The Cytokine Network in Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0220tr · Cited by 412
MAGNETIC NANOPARTICLE HYPERTHERMIA IN CANCER TREATMENT
GIUSTINI, A. J., PETRYK, A. A., CASSIM, S. M., TATE, J. A., BAKER, I., & HOOPES, P. J. (2010) · Nano LIFE · doi:10.1142/s1793984410000067 · Cited by 390
Magnetic nanoparticles for the manipulation of proteins and cells
Pan, Y., Du, X., Zhao, F., & Xu, B. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15315g · Cited by 376
Formulation and delivery issues for monoclonal antibody therapeutics
Daugherty, A. L., & Mrsny, R. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.011 · Cited by 351
CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels
Chini, C. C. S., Peclat, T. R., Warner, G. M., Kashyap, S., Espindola-Netto, J. M., de Oliveira, G. C., Gomez, L. S., Hogan, K. A., Tarragó, M. G., Puranik, A. S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00298-z · Cited by 349
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
“Addition of PEG to bsAbs has been shown to improve the serum half-life [26], but this often alters the binding affinities of bsAbs [27], which might affect tumor targeting.”
BackgroundImmuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 330
Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up
Vignard, J., Mirey, G., & Salles, B. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.013 · Cited by 315
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00283 · Cited by 310
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N., Hamieh, M., Hegde, M., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 303
Alternative non-antibody scaffolds for molecular recognition
Skerra, A. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.04.010 · Cited by 300
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Richards, D. A., Maruani, A., & Chudasama, V. (2017) · Chemical Science · doi:10.1039/c6sc02403c · Cited by 294
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
Nygren, P. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06438.x · Cited by 282
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2007) · Cancer · doi:10.1002/cncr.22402 · Cited by 281
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
TRAIL on trial: preclinical advances in cancer therapy
Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 276
Development and Applications of Portable Biosensors
Srinivasan, B., & Tung, S. (2015) · SLAS Technology · doi:10.1177/2211068215581349 · Cited by 262
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H., & Hackenberger, C. P. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708459 · Cited by 260
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Maruani, A., Smith, M. E. B., Miranda, E., Chester, K. A., Chudasama, V., & Caddick, S. (2015) · Nature Communications · doi:10.1038/ncomms7645 · Cited by 256
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
DARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Self-citationAffinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
RosettaAntibodyDesign (RAbD): a general framework for computational antibody design
Adolf-Bryfogle, J., Kalyuzhniy, O., Kubitz, M., Weitzner, B. D., Hu, X., Adachi, Y., Schief, W. R., & Dunbrack, R. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006112 · Cited by 227
“companies, government, and academia[1-7].”
Computational approaches to therapeutic antibody design: established methods and emerging trends
Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219
“Some of these include Fab domains and other modular formats with single chain Fvs (scFv) (linked VH and VL domains) as the main component, e.g. scFv, (scFv)2, diabody and minibody (reviewed by Holliger and Hudson [38], Farajnia et al. [39] and Kwon et al. [40]).”
BackgroundAntibody-based therapies for malaria
Pleass, R. J., & Holder, A. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1267 · Cited by 182
Skerra, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06439.x · Cited by 176
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“and Hudson [273].”
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“2 Antibody fragments Recent advances in bioengineering have led to the the development of antibody fragments such as Fab (50 kDa), F(ab’)2 (110kDa), 25-kDa single-chain Fv (scFv), diabodies (55 kDa), nanobodies (15kDa) and minibodies (80 kDa) without affecting their affinity and specificity [94].”
BackgroundA Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W. W. A., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0348-6 · Cited by 82
“preparation of recombinant BsAbs as dimeric antibody fragments [12].”
BackgroundInfluentialOw, D., Lim, D., Morin Nissom, P., Camattari, A., & Wong, V. (2010) · Microbial Cell Factories · doi:10.1186/1475-2859-9-22 · Cited by 49
Sonoda, H., Kumada, Y., Katsuda, T., & Yamaji, H. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2010.12.015 · Cited by 45
Cossins, A. J., Harrison, S., Popplewell, A. G., & Gore, M. G. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2006.07.013 · Cited by 21
Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E. coli
Kulmala, A., Huovinen, T., & Lamminmäki, U. (2017) · Scientific Reports · doi:10.1038/s41598-017-03957-6 · Cited by 20
“After digestion, target fragments (1) 1273 bpV1, (2) 1094 bpV2 and 131 bpV2, (3) 734 bpV3 and 310 bpV3 were obtained by gel extraction.”
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16
Rezaie, F., Davami, F., Mansouri, K., Agha Amiri, S., Fazel, R., Mahdian, R., Davoudi, N., Enayati, S., Azizi, M., & Khalaj, V. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13483 · Cited by 15
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Thermodynamic Stability and Flexibility Characteristics of Antibody Fragment Complexes
Li, T., Verma, D., Tracka, M., Casas-Finet, J., Livesay, D., & Jacobs, D. (2013) · Protein & Peptide Letters · doi:10.2174/09298665113209990051 · Cited by 13
Metadata
- Authors
- Holliger, P., & Hudson, P. J.
- Venue
- Nature Biotechnology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 9
- Pages
- 1126-1136
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1993575340
- Cited by
- 1,931
- References
- 107
- FWCI
- 53.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.